All In Biotech

Drug Trial Radar · NCT04685226

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Sep 27, 2020

Primary completion

Jan 25, 2028

Study completion Feb 25, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors

Conditions

  • Solid Tumors

Interventions

  • ICP-723Drug

    ICP-723 is a white, round, uncoated table

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 12 months
  2. MTDTime frame: Up to 2 Months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Medical Center of the Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Cancer Hospital Affiliated to Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangdong, Guangzhou, China · Recruiting

  • Shijiazhuang People's Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Cancer Hospital Affiliated to Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The first affiliated hospital Zhejiang university school of medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.